Welcome to our dedicated page for DRNA news (Ticker: DRNA), a resource for investors and traders seeking the latest updates and insights on DRNA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DRNA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DRNA's position in the market.
Dicerna Pharmaceuticals (Nasdaq: DRNA) has approved inducement grants for a new employee, comprising stock options to purchase 31,875 shares and 7,125 restricted stock units (RSUs) effective April 1, 2021. The stock options, with an exercise price of $25.76, vest over four years, while the RSUs vest similarly, with 25% vesting on March 15, 2022, and annually thereafter. These grants comply with Nasdaq listing Rule 5635(c)(4) and form part of Dicerna’s commitment to advancing RNA interference (RNAi) therapies addressing various diseases.
Dicerna Pharmaceuticals (Nasdaq: DRNA) announced promising preclinical data for its GalXC-Plus RNAi technology, highlighting its ability to achieve deep and sustained mRNA knockdown in the central nervous system (CNS). In mouse studies, a single dose resulted in up to 92% mRNA reduction over 28 days, while non-human primate studies demonstrated similar efficacy with 90% knockdown. No adverse effects were reported. The results suggest broad therapeutic potential for CNS diseases, positioning Dicerna for advancements beyond its liver-targeted GalXC platform.
Dicerna Pharmaceuticals (Nasdaq: DRNA) announced that Maire Osborn, Ph.D., will present new nonclinical data on GalXC-Plus™ RNAi technology at the Oligonucleotide and Precision Therapeutics Virtual Congress on March 30-31, 2021. The keynote presentation titled “GalXC-Plus: Cell-Type Targeted Therapeutic Oligonucleotide Delivery in the CNS,” will discuss targeted delivery and durability of action in the central nervous system. The presentation will be available on Dicerna's website post-event. Dicerna focuses on RNAi technologies to treat diseases by silencing specific genes.
Dicerna Pharmaceuticals (Nasdaq: DRNA) will host a webinar on March 18, 2021, at 4:30 p.m. ET to discuss its alcohol use disorder (AUD) candidate, DCR-AUD. Expert Henry Kranzler, M.D., will join the management team to cover significant topics including the epidemiology of AUD, the mechanism of DCR-AUD targeting ALDH2, and the planned Phase 1 clinical trial. Interested participants can access the webinar through the 'Investors & Media' section of Dicerna's website, with pre-registration recommended for timely connection.
Dicerna Pharmaceuticals (Nasdaq: DRNA) announced the initiation of Roche's RG6346 in a Phase 2 trial for chronic hepatitis B virus (HBV) infection. This milestone earns Dicerna $25 million. RG6346, an investigational GalXC™ RNAi therapeutic, aims to provide a functional cure for HBV, which affects around 292 million people globally. Early Phase 1 results show substantial and sustained HBsAg reductions. The trial will explore multiple combination therapies, with the primary goal of achieving HBsAg loss at 24 weeks post-treatment.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) reported significant growth in the full year 2020, highlighting revenue of $164.3 million, up from $23.9 million in 2019, largely due to collaborations with Roche, Alexion, and Lilly. The company has a robust cash position of $568.8 million as of December 31, 2020. Dicerna plans to advance its clinical pipeline, including pivotal-stage candidates for primary hyperoxaluria and alcohol use disorder, with expectations for continued collaboration funding. However, R&D expenses have also risen sharply to $205.4 million.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) announced participation in key investor conferences. Douglas M. Fambrough, Ph.D., will engage in a fireside chat at the SVB Leerink Global Healthcare Conference on February 24, 2021, at 3:00 p.m. ET, followed by a presentation at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET. Audio webcasts will be available on the Dicerna website, with archived replays accessible post-event. Dicerna focuses on RNAi therapeutics targeting disease-causing genes, leveraging proprietary technologies to develop treatments for various diseases.
Dicerna Pharmaceuticals (Nasdaq: DRNA) will announce its financial results for the year ending December 31, 2020, after market close on February 25, 2021. A conference call to discuss these results and provide a business update will commence at 4:30 p.m. ET the same day. Interested parties can access the call by dialing in or via the Dicerna website. The company focuses on RNA interference therapeutics and collaborates with leading pharmaceutical firms to explore over 20 active programs targeting various diseases.
Dicerna Pharmaceuticals (Nasdaq: DRNA) announces the initiation of patient dosing in its PHYOX™4 clinical trial for nedosiran, targeting primary hyperoxaluria type 3 (PH3). This milestone aims to address unmet medical needs in PH3, a rare genetic disorder. The randomized, placebo-controlled trial seeks to evaluate the safety and efficacy of a single dose of nedosiran in patients with a history of kidney stones. The study plans to enroll six participants, with results expected in mid-2021, supporting a New Drug Application (NDA) submission anticipated in Q3 2021.
Dicerna Pharmaceuticals (Nasdaq: DRNA) has announced that its CEO, Douglas M. Fambrough, will participate in two events at the H.C. Wainwright Virtual BioConnect Conference from Jan. 11-14, 2021. On Jan. 11 at 12:00 p.m. ET, he will engage in an analyst-led fireside chat and a panel discussion titled, 'Clinical Trial Design', moderated by former FDA Commissioner Scott Gottlieb, M.D. The fireside chat will be available on demand from 6:00 a.m. ET that day. Webcasts can be accessed via Dicerna's Investor section on their website.
